Scots-Knight Denise

SEC source: 0001297000-26-000003 · form4-05262026_080544.xml · nonDerivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,588

F2 · shares: Grant of restricted stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0001297000-26-000003 · form4-05262026_080544.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 93,392

F1 · shares: Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0001193125-26-033751 · ownership.xml · derivative · entry 3

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 480,000

Underlying: American Depository Shares · 480,000 shares

Expires 2036-02-01

F3 · derivative.exercise_date: Vests in substantially equal monthly installments over a one year period from the February 1, 2026 grant date.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001193125-26-033751 · ownership.xml · derivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 345,000

Underlying: American Depository Shares · 345,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001193125-26-033751 · ownership.xml · derivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,035,000

Underlying: American Depositary Shares · 1,035,000 shares

Expires 2036-02-01

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on February 1, 2027, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001297000-25-000006 · form4-12022025_101247.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,714

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0000950170-25-009787 · ownership.xml · derivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 825,000

Underlying: American Depository Shares · 825,000 shares

Expires 2035-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2026, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001415889-24-028148 · form4-12032024_101228.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,400

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0000950170-24-106976 · ownership.xml · nonDerivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 808,921

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.01 to $4.43, inclusive.

F6 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-106976 · ownership.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 868,967

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.

F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $4.37 to $4.62, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4.

F6 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-106417 · ownership.xml · derivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: American Depository Shares · 188,060 shares

Expires 2025-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0000950170-24-106417 · ownership.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 897,578

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period.

F4 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-078465 · ownership.xml · nonDerivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 709,518

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.28 to $3.51, inclusive.

F6 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-078465 · ownership.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 801,791

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F2 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.

F3 · shares: Represents the number of ADSs required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Performance-based restricted stock units under the issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on June 21, 2024. These sales are mandated by the Issuer's election under its Plan to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These ADSs were sold in multiple transactions at prices ranging from $3.60 to $3.805, inclusive. The Reporting Person undertakes to provide to Mereo BioPharma Group plc ("Mereo"), any security holder of Mereo, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of ADSs sold at each separate price within the ranges set forth in footnotes (4) and (5) to this Form 4.

F6 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-077482 · ownership.xml · derivative · entry 2

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 188,060

Underlying: American Depository Shares · 282,090 shares

Expires 2025-01-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0000950170-24-077482 · ownership.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 842,503

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

F3 · security: Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer.

F2 · shares: Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025).

F4 · balance_after: Includes 1,200 ADSs jointly owned by Reporting person and her spouse.

SEC source: 0000950170-24-007934 · ownership.xml · derivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 850,000

Underlying: American Depository Shares · 850,000 shares

Expires 2034-01-25

F1 · derivative.exercise_date: 25% of the shares underlying this share option will vest and become exercisable on January 25, 2025, with the remainder vesting in equal monthly installments for the three years thereafter.

F2 · derivative.underlying: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.

SEC source: 0001415889-23-015778 · form4-12042023_101202.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,231

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0001415889-22-011975 · form4-12022022_101209.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,857

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0001179110-21-010523 · edgar.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,208

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0000950138-20-000515 · edgar.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,901

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0000950138-21-000127 · edgar.xml · derivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 987.2356

Underlying: Common Stock · 99.038 shares

Expires not disclosed

F1 · security: Ms. Scots-Knight elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

F2 · security: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

F3 · derivative.exercise_price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.45 on December 31, 2019.

F2 · price: The Deferred Stock Units will be settled in stock upon the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

F3 · price: The number of Deferred Stock Units issued is the amount of cash compensation deferred divided by the closing price of a share of Elanco common stock on the grant date, which was $29.45 on December 31, 2019.

F1 · derivative.exercise_date: Ms. Scots-Knight elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

F1 · derivative.expiration_date: Ms. Scots-Knight elected to defer his director cash retainer fees pursuant to the Company's Directors' Deferral Plan (the "Plan") and such deferred fees were credited to the Elanco Deferred Stock Account under the Plan. Each Deferred Stock Unit is the economic equivalent of one share of Elanco common stock.

F4 · balance_after: Represents an aggregate amount of Deferred Stock Units owned by the reporting person as of fiscal year end, which includes Deferred Stock Units which were inadvertently excluded from prior filings, awarded during the years of 2019. The number of Deferred Stock Units issued on each such award date is the amount of cash deferred divided by the closing price of a share of Elanco common stock on the award date.

SEC source: 0000950138-19-000581 · edgar.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,016

F1 · price: Grant of deferred stock units as an annual equity award to each of the non-employee members of the Issuer's Board of Directors.

SEC source: 0000950138-19-000254 · edgar.xml · nonDerivative · entry 1

Scots-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,783

F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant.

SEC source: 0001140361-18-029841 · doc1.xml · derivative · entry 1

Pollard-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2028-06-22

F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0001209191-17-041075 · doc4.xml · derivative · entry 1

Pollard-Knight Denise · CIK 0001297000 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,000

Underlying: Common Stock · 3,000 shares

Expires 2027-06-15

F1 · derivative.exercise_date: This option will vest and become exercisable in full on the earlier of (i) June 16, 2018 or (ii) the day prior to the issuer's 2018 annual meeting of stockholders, subject to the director's continued service on the issuer's board of directors on the vesting date.

SEC source: 0001140361-17-023621 · doc1.xml · derivative · entry 1

Pollard-Knight Denise · CIK 0001297000 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 15,000 shares

Expires 2027-06-01

F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

SEC source: 0001209191-17-005551 · doc4.xml · derivative · entry 1

Pollard-Knight Denise · CIK 0001297000 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,500

Underlying: Common Stock · 4,500 shares

Expires 2027-01-22

F1 · derivative.exercise_date: This option will vest and become exercisable in equal annual installments on the first three anniversaries of the date of grant (but, in any case, to be fully vested on the day prior to the annual meeting for the third fiscal year that begins following the date of grant).

SEC source: 0001209191-16-148723 · doc4.xml · nonDerivative · entry 1

Pollard-Knight Denise · CIK 0001297000 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Held by Phase4 Ventures III GP LP

Disclosed balance after: 1,165,447

F1 · shares: Represents shares of common stock of Albireo Pharma, Inc. (the "Issuer"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited ("Albireo") and the holders of Albireo shares and notes convertible into Albireo shares.

F2 · ownership.nature: Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Denise Scots-Knight may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaims beneficial ownership except to the extent of her pecuniary interest therein, if any.